Fig. 2From: Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA studyEvolution of REVEAL risk strata after at least six months on macitentan. Grouped risk categories: 1–7 low risk, 8–9 average-moderate high risk, ≥10 high-very high riskBack to article page